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ABSTRACT
CD3/CD28 co-stimulation activates T-cell cytokine and cytolytic effector function and therefore represents an
approach to modulate donor T cells before allogeneic bone marrow transplantation (BMT). We hypothesized
that co-stimulation of donor T cells under T2 conditions would generate CD4 T-helper type 2 (Th2) and
CD8 Tc2 cells capable of abrogating marrow graft rejection with reduced graft-versus-host disease (GVHD).
Relative to control co-stimulated Th1/Tc1 (T1) cells, co-stimulated T2 cells secreted reduced interleukin
(IL)–2 and interferon- and increased IL-4 and IL-10, expressed reduced fas ligand, and had similar total
cytolytic capacity. In an F1-into-parent sublethal irradiation model, T2 cells potently abrogated rejection; this
veto effect was partially attenuated if T2 cell infusion was delayed for 24 hours after BMT. Cell-tracking studies
determined that T2 cells were quantitatively reduced after BMT when administered to hosts capable of
mounting a host-versus-graft rejection response; both donor and host cytotoxic T lymphocytes may therefore
have been deleted during Th2/Tc2 cell facilitation of engraftment. Donor T2 cells also abrogated rejection in
an F1-into-parent model that used lethal host irradiation and subsequent host T-cell addback. Further
experiments in a P1-into-P2 transplantation model demonstrated that donor T2 cells abrogated rejection with
reduced GVHD in a transplant setting involving full major histocompatibility complex disparity in both the
host-versus-graft and graft-versus-host directions. The capacity of T2 cells to abrogate rejection with reduced
GVHD was a function of both the number of T2 cells infused and the number of T cells present after host
preparation. Co-stimulation under T2 polarizing conditions therefore rapidly generates donor Th2/Tc2 cells
that potently abrogate murine marrow rejection with reduced GVHD.
© 2004 American Society for Blood and Marrow Transplantation
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(NTRODUCTION
Although allogeneic bone marrow transplantation
BMT) represents a curative treatment for many pa-
ients with malignant and nonmalignant diseases, graft
ejection limits more complete application of this
herapy. Most patients lack an HLA-matched sibling
onor [1], and transplantation of T cell–depleted
TCD) marrow grafts across genetic barriers is asso-
iated with a signiﬁcant rate of graft rejection [2].
ttempts to increase stem cell dose and to further
ntensify myeloablative conditioning regimens can
uccessfully abrogate rejection in mismatched trans-
lantation, but this approach has been limited by a
igniﬁcant incidence of transplant-related mortality s
04nd opportunistic infections [3]. The retention of T
ells within allogeneic stem cell grafts can overcome
raft rejection, but this is associated with graft-versus-
ost disease (GVHD); attempts to identify a donor
-cell dose that consistently abrogates rejection with-
ut inducing a signiﬁcant incidence of severe GVHD
ave been unsuccessful [4]. Identiﬁcation of T-cell
opulations that prevent rejection with reduced
VHD is therefore desired, and, to this end, we
valuated CD3/CD28 co-stimulated T cells of the
-helper type 2 (Th2)/Tc2 phenotype for their ability
o prevent fully major histocompatibility complex
MHC)–disparate marrow graft rejection.
Graft-versus-host reaction can be experimentally
eparated from host-versus-graft (HVG) reaction by
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Co-Stimulated Th2/Tc2 Cells Abrogate Marrow Rejection
Bransplanting F1 marrow and T cells into parental
osts (F1-into-P model). In these models, donor T
ells are not able to respond to host alloantigens, and
n HVG reaction is therefore induced without ongo-
ng GVHD. As such, an ability of donor T cells to
brogate graft rejection in these models occurs by a
on–host-reactive veto-type mechanism [5]. T-cell
opulations that abrogate rejection in these models
re candidates for preventing rejection with reduced
VHD. In some cases, the veto effect is mediated by
onor T cells with mature effector function that are
apable of clonally deleting host-type precursor cyto-
oxic T lymphocytes (CTLs) upon CTL recognition
f donor alloantigens [6]. Donor populations capable
f preventing in vivo rejection in F1-into-P models
ave included natural killer cells [7], CD8 T cells
5,8], and CD4 T cells [5].
We have previously shown that CTLs of the Tc2
henotype, deﬁned by their preferential secretion of
he type II cytokines interleukin (IL)–4 and IL-10, are
nriched in their capacity to prevent graft rejection by
uch a non–host-reactive mechanism [9]. In that prior
tudy, Tc2 cells were generated in vitro through stim-
lation with third-party antigen-presenting cells
APC). Administration of T cells of the type II cyto-
ine phenotype is a potentially useful approach to
acilitate engraftment: in vitro–generated donor anti-
ost allospeciﬁc T cells of the type II cytokine phe-
otype signiﬁcantly reduced GVHD after fully MHC-
ismatched transplantation [10,11]. Recently, we
ave demonstrated that CD3/CD28 co-stimulation of
onor T cells in the presence of IL-4 generates a mix
f Th2 and Tc2 cells that have reduced clonal expan-
ion to alloantigen in vivo mediate reduced GVHD
12]. In light of these data, we evaluated whether
o-stimulated donor Th2/Tc2 cells might abrogate
ejection in an F1-into-P model, in which GVHD
oes not occur on a genetic basis, and in a P1-into-P2
odel, in which GVHD might be reduced because of
unctional attributes of the T2 cells, such as type II
ytokine secretion or reduced clonal expansion to al-
oantigen. In addition, we evaluated T2 cells for their
bility to abrogate marrow rejection in a newly de-
cribed rejection model that involves lethal host irra-
iation and quantitative host T-cell addback.
ATERIALS AND METHODS
ice
Six- to 10-week-old female BALB/c (H-2d),
57BL/6 (H-2Kb), and (C57BL/6  BALB/c)F1
CB6F1, H-2K
b/d) mice were obtained from the Fred-
rick Cancer Research Facility (Frederick, MD) and
aintained in a speciﬁc-pathogen-free facility. All ex-
eriments were performed according to an approved
nimal protocol. R
B&MTeagents and Antibodies
Complete media (CM) consisted of RPMI 1640
Life Technologies, Rockville, MD) supplemented
ith penicillin, streptomycin, nonessential amino ac-
ds, 2-mercaptoethanol (Life Technologies), and 10%
etal bovine serum (Gemini, Woodland, CA). ACK
ysing buffer (Quality Biological, Gaithersburg, MD),
anks balanced salt solution (HBSS; Mediatech Cell-
ro, Herndon, VA), and DPBS (Biosource Interna-
ional, Camarillo, CA) were used for cell preparation.
nti-CD3 and anti-CD28 (clones 145-2C11 and
7.51; PharMingen, San Diego, CA) were used to
enerate coated beads (3/28 beads; tosyl-activated
450 Dynabeads; Dynal, Lake Success, NY) by using
previously described method [13].
For ﬂow cytometry, anti–H-2Kb (clone AF6-88.5),
nti–H-2Kd (clone SF1-1.1), mouse immunoglobulin
Ig)G2a (phycoerythrin and ﬂuorescein isothiocya-
ate), anti-CD4 (clone RM4-5), anti-CD8 (clone 53-
.7), anti-CD25 (clone PC61), anti-CD69 (clone
1.2F3), anti-CD62L (clone MEL-14), rat IgG2a
phycoerythrin and ﬂuorescein isothiocyanate), and
c-receptor blocking reagent (anti-CD16/CD32; Fc
II/II receptor) were all purchased from PharMingen.
ovine serum albumin (ICN Biochemicals, Aurora,
H), sodium azide, and propidium iodide were ob-
ained from Sigma (St. Louis, MO).
CTL assays used chromium 51 (51Cr; Amersham,
iscataway, NJ), ethylene glycol-bis-(-aminoethyl
ther)-N,N,N,N-tetraacetic acid (EGTA; Sigma),
agnesium chloride (Quality Biological), 4-(2-hy-
roxyethyl)-1-piperazineethanesulfonic acid (HEPES;
ediatech), phorbol 12-myristate 13-acetate and cal-
ium ionophore (both from Sigma), and sodium do-
ecyl sulfate 20% (Oncor, Gaithersburg, MD). suc-
inimidyl ester 5-(and -6) carboxyﬂuorescein diacetate
CFDA) was purchased from Molecular Probes (Eu-
ene, OR). For T-cell depletion, anti-CD4 (clone
K1.5) and anti-CD8 (clone 2.43) were obtained
rom the National Cancer Institute Biological Re-
ource Branch (NCI-BRB, Frederick, MD). Goat
nti-rat IgG and goat anti-mouse (GAM) IgG-coated
ioparticles were from Polysciences (Warrington,
A).
Cytokines and antibodies for in vitro culture were
ecombinant human (rh)IL-2 (NCI-BRB); anti–IL-4
clone 11B11; NCI-BRB); rhIL-7, recombinant
ouse (rm)IL-12, and rmIL-4 (Peprotech, Rocky
ill, NJ); and 20%N-acetylcysteine solution (Bedford
aboratories, Bedford, OH).
D3/CD28 Generation of Donor T1 and T2 Cells
Splenic single-cell suspensions were obtained
rom F1 or BALB/c mice. Red blood cells were ACK-
ysed, and B cells were removed with GAM beads.
6esultant T cells (0.3 10 /mL) were stimulated with
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6/28 beads (bead-cell ratio of 3:1) at 37°C in a 5%
umidiﬁed CO2 chamber. The T1 culture condition
ontained rhIL-2 (20 IU/mL), rhIL-7 (20 ng/mL),
mIL-12 (10 ng/mL), anti–IL-4 (10 g/mL), and 3.3
mol/L N-acetylcysteine. The T2 culture contained
hIL-2 (1000 IU/mL), rhIL-7 (20 ng/mL), rmIL-4
1000 U/mL), and 3.3 mmol/LN-acetylcysteine. Cells
ere maintained at 0.2 to 0.5  106/mL by daily
ddition of T1- or T2-speciﬁc media. However, IL-12
as added only on day 0 of T1 culture. Cells were
sed for in vitro and in vivo experiments on culture
ay 4. Cell number and cell volume were measured
ith a Coulter Multisizer (Beckman Coulter, Miami,
L).
ytokine Secretion Assay by Enzyme-Linked
mmunosorbent Assay
After T-cell culture under T1 or T2 conditions,
ells were harvested, adjusted to 0.5  106/mL in CM
ithout cytokine support, and were re-stimulated with
/28 beads for 24 hours. Supernatants were collected,
nd cytokine content was measured by using 2-site
nzyme-linked immunosorbent assay (IL-2 assay:
&D Systems, Minneapolis, MN; IL-4, IL-10, and
nterferon [IFN]– assays: Biosource).
ytotoxicity Assays by Chromium Release
The cytolytic capacity of the T1 and T2 cells was
ssessed on day 4 of culture by 51Cr release assay. For
easurement of total cytolytic function, a bispeciﬁc
ntibody heteroconjugate assay was performed as de-
cribed previously [14]. Jurkat targets were labeled
ith 51Cr and trinitrobenzene sulfonate (TNP);
NP-labeled targets were then incubated with T1
nd T2 cells for 4 hours. Before target cell co-incu-
ation, T1 and T2 cells were incubated with bispeciﬁc
nti-CD3 and anti-TNP (provided by David Segal,
ational Institutes of Health, Bethesda, MD).
To measure nongranule exocytosis-based killing,
1Cr assays were performed in a calcium-neutralized
ondition (EGTA 5 mmol/L, MgCl 0.5 mmol/L, and
EPES 25 mmol/L) [15]. To induce fas ligand, T1
nd T2 cells were stimulated with phorbol 12-myris-
ate 13-acetate (5 ng/mL) and calcium ionophore (375
g/mL) for 12 to 16 hours in CM. Fas-transfected
1210 cells (L1210-fas; H-2Kd) served as positive
ontrol targets, whereas wild-type L1210 cells were
sed as a negative control (lines were provided by
ierre Henkart, National Institutes of Health). Effec-
or T1 and T2 populations were incubated with
1210-fas or L1210 targets for 8 hours in CM.
Supernatants were harvested, transferred to Luma
lates (Packard, Downers Grove, IL), and read with a
icroplate Scintillation and Luminescence Counter
Packard). Minimal lysis was determined by incuba-
ion of each target in CM, whereas maximum lysis was w
06etermined by target incubation in sodium dodecyl
ulfate 20%. Speciﬁc target lysis was calculated by
arget lysis (%)  (cpm sample  cpm minimum)/
(cpm maximum  cpm minimum)  100,
here cpm indicates counts per minute.
one Marrow Transplantation
F1 or BALB/c bone marrow cells were removed
rom the tibia and femur aseptically and were T cell–
epleted by incubation with anti-CD4 and anti-CD8
ntibodies followed by incubation with goat anti-rat
eads. TCD bone marrow cells (5  106) with or
ithout T1 or T2 cells (1.0 or 2.5  107) were resus-
ended in HBSS and transplanted by intravenous in-
ection into irradiated recipients (cesium 137 radiation
ource, 100 cGy/min; Gamma Cell 40; Atomic Energy
f Canada, Ltd., Ottawa, Ontario, Canada). The irra-
iation dose is indicated in each experiment; 1050- or
200-cGy doses were split, with 6 hours between each
doses. In the experiments involving host T-cell add-
ack, mice were irradiated on day 2, host T cells
ere “added back” on day 1, and BMT with or
ithout donor T-cell infusion was performed on day
. Host T cells were obtained through isolation of
plenic single cells, followed by B-cell removal with
AM beads. Graft rejection was diagnosed by ﬂow
ytometry (sublethal irradiation model) or by survival
nalysis (lethal irradiation models).
low Cytometry
For surface staining of T1 and T2 cells, 1  106
ells were washed in HBSS containing 1% bovine
erum albumin and 0.5% sodium azide, incubated
ith antibodies or isotype controls, and washed. Two-
olor ﬂow cytometry was performed (FACSCalibur
sing CellQuest software; Becton Dickinson Immu-
ocytometry Systems, Mountain View, CA). A total of
000 to 10000 events were acquired; dead cells were
ated out by propidium iodide staining. To assess
himerism, mice were bled from the retro-orbital si-
us, cells were Fc-blocked, and samples were stained
ith appropriate H-2K antibodies or isotype controls.
ed blood cells were lysed by ACK. Peripheral blood
ymphocytes obtained from untreated B6 and F1 mice
ere used to deﬁne positive and negative quadrants.
ecipients with 	2% of cells positive for both H-2Kb
nd H-2Kd were considered not to have engrafted.
n Vivo T Cell–Tracking Studies
For enumeration of T1 and T2 cells after BMT,
1-type T1 or T2 cells were generated and harvested,
ashed in DPBS, incubated with 1 mol/L 5(6)-
FDA, SE (CFDA) at 37°C for 10 minutes, washed
ith 100% fetal calf serum, incubated in CM without
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Co-Stimulated Th2/Tc2 Cells Abrogate Marrow Rejection
BFDA at 37°C for 15 minutes, and ﬁnally washed in
M 3 times. CFDA-labeled cells were then co-in-
ected with 5  106 TCD marrow cells into irradiated
700 cGy) B6 or F1 host mice. Spleen cells were
arvested after 4 and 40 hours after BMT, counted,
nd analyzed by ﬂow cytometry.
tatistical Analysis
Two-sided P values were obtained by using the
igure 1. Characterization of in vitro–generated donor Th1/T
onor T cells were stimulated with anti-CD3/anti-CD28 beads
n T-cell number (left panel) and change in T-cell activation, a
ean 
 SEM of 3 experiments. B, Cytokine phenotype of T1 and
nd re-stimulated with anti-CD3/anti-CD28 beads. Resultant 2
inked immunosorbent assay. Values shown are mean 
 SEM of
er 0.5  106 cells per 24 hours. C, Cytolytic capacity of T1 a
eteroconjugate assay (left panel). 51Cr-labeled Jurkat cells we
ispeciﬁc antibody. Non–granule-mediated killing was tested by 5
ere stimulated with phorbol 12-myristate 13-acetate and cal
L1210-fas). CTL results show 1 representative experiment outtudent t test. c
B&MTESULTS
D3/CD28 Activated T1 and T2 Populations:
ell Expansion and Activation
T cells co-stimulated in either T1 or T2 culture
onditions expanded signiﬁcantly (Figure 1A, left
anel), with approximately 30-fold and 100-fold ex-
ansion by days 4 and 6 of culture. CD8 T cells
referentially expanded, because both T1 and T2
ultures typically consisted of 70% to 80% CD8 T
) and Th2/Tc2 (T2) cells. A, T-cell expansion and activation.
e 1 or type 2 culture conditions. Data shown are -fold increase
ured by median cell volume (femtoliters; right panel); data are
pulations. Co-stimulated cells were harvested on day 4 of culture
r supernatants were analyzed for cytokine content by enzyme-
iments; cytokine values are expressed as picograms per milliliter
cells (day 4 of culture). Total lytic potential was evaluated by
ets; assay was performed with or without anti-CD3/anti-TNP
say in Ca2-neutralized conditions (right panel). T1 and T2 cells
onophore; targets were wild type (L1210) or fas transfectedc1 (T1
in typ
s meas
T2 po
4-hou
3 exper
nd T2
re targ
1Cr as
cium iells at day 6 of culture (not shown). In prior studies
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6ith APC-free co-stimulation of human T cells,
edian cell volume (MCV) represented a reliable
easure of T-cell activation [16]. We observed a
-fold increase in MCV in both T1 and T2 condi-
ions by day 2, with a gradual decline in MCV by
ay 6 (Figure 1A, right panel). Other experiments
onﬁrmed that the T1 and T2 cells had an activated
ffector phenotype, as indicated by increased ex-
ression of CD25, CD69, and CD44 and reduction
f CD62L (data not shown).
o-stimulated T1 and T2 Cells: Cytokine
ecretion and Cytolytic Function
At day 4 of culture, co-stimulation under the type
condition generated T cells that produced IFN-
nd IL-2 and greatly reduced IL-4 and IL-10 (Figure
B). In marked contrast, T cells expanded under the
ype 2 condition secreted increased IL-4 and IL-10,
ndetectable IL-2, and reduced IFN-. Because co-
timulation maintains a polyclonal repertoire not en-
iched for antigen speciﬁcity [16], the total cytolytic
unction of the T1 and T2 populations was evaluated
y using a bispeciﬁc heteroconjugate assay (Figure 1C,
eft panel). Both T1 and T2 cells had potent cytolytic
unction in this assay, which is performed in calcium-
ontaining media and therefore reﬂects total lytic po-
ential through granule-mediated and other pathways.
1 and T2 cells did not mediate lysis in this assay
hen performed in calcium-neutralized conditions
data not shown); as such, nongranule pathways such
s fas ligand did not signiﬁcantly contribute to cytol-
sis in this assay. To evaluate nongranule exocytosis-
ased killing, CTL assays were performed in Ca2-
eutralized media by using fas-transfected L1210 cells
L1210-fas) as targets (Figure 1C, right panel). T1
able 1. F1-into-P Sublethal Irradiation Model: T1 versus T2 Abroga
Treatment Group*
ohort No. Host XRT BMT (F1) T Cells (F1)
1 1200  —
2 700  —
3 700  T1 (day 0)
4 700  T2 (day 0)
5 700  T1  T2 (day 0
6 700  T2 (day 1)
7 700  T2 (day 2)
Host B6 mice were irradiated (XRT) at the doses indicated and rec
T1 cells (1  107), T2 cells (1  107), or T1 and T2 cells (5 
cells (1  107) on day 1 or 2 of BMT.
Results were pooled from 2 experiments. Day 90 post-BMT blood
(H-2Kb/d) and host-type cells (H-2Kb). % donor chimerism [d
limit (	2%).ells potently lysed the L1210-fas target, but not the (
081210 control target. By comparison, T2 cells had
educed ability to lyse L1210-fas targets.
1-into-P Sublethal Irradiation Model: T2 Cell
brogation of Rejection
Results of the F1-into-P BMT are shown in Table
. At 1200 cGy of host irradiation, engraftment oc-
urred in all recipients of TCD F1 marrow; at 700 cGy
f irradiation, graft rejection occurred in all recipients
f TCD marrow alone. Supplementation of TCD
arrow with co-stimulated T2 cells abrogated rejec-
ion (7/7 cases; day 90 mean chimerism was 94.3%). In
ontrast, co-stimulated T1 cells were less effective
3/8 cases engrafted; of engrafted recipients, day 90
ean chimerism was 83.7%). T2 cells were more
ffective than T1 cells (P  .006). Because T1 and T2
opulations had differential cytokine and cytolytic ef-
ector function, we hypothesized that mixing T1 and
2 cells might conserve or enhance rejection abroga-
ion. However, 1 of 4 recipients in the T1/T2 com-
ination group had greatly reduced donor chimerism
3%).
Because T2 cell abrogation of rejection in this
1-into-P model may involve clonal deletion of host
recursor CTL (pCTL) after their activation toward
onor alloantigen [6,17], we hypothesized that delay
f T2 cell infusion within the window of pCTL acti-
ation may enhance, or at least not reduce, T2 cell
fﬁcacy. In vitro, this window of pCTL susceptibility
o deletion is typically 24 to 72 hours. To test this
ypothesis, co-stimulated T2 cells were injected at the
ime of BMT (day 0) or at 24 or 48 hours after BMT
Table 1). Contrary to our hypothesis, this short delay
n cell infusion reduced T2 cell efﬁcacy: graft rejection
as observed in 3 of 8 cases and mixed chimerism
Rejection
Engraftment†
Rate % Donor Chimerism Statistics
8/8 93, 96, 97, 97, 97, 98, 98, 100
0/10 <, <, <, <, <, <, <, <, <, <
3/8 <, <, <, <, <, 71, 84, 96 3 vs 2 (P  .040)
7/7 87, 91, 95, 96, 96, 97, 98 4 vs 3 (P  .006)
4 vs 6 (P  .052)
4 vs 7 (P  .004)
4/4 3, 93, 95, 97
3/4 <, 11, 73, 92,
2/4 <, <, 15, 55
MT (5  106 TCD F1 marrow cells). Cohorts 3, 4, and 5 received
each population) on day 0 of BMT. Cohorts 6 and 7 received T2
valuated by ﬂuorescence-activated cell sorting for donor-type cells
onor host)] 100%.	 indicates chimerism below the detectiontion of
)
eived B
106 of
was e
onor/(d	90% donor) was observed in 4 of 8 cases.
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B2 Cell Numbers Are Reduced after BMT in
arental Hosts, but Not Syngeneic Hosts
Because both T1 and T2 populations were potent
ytolytic effectors in vitro, the mechanisms contribut-
ng to the enhanced potency of T2-mediated abroga-
ion of rejection are not clear. One relatively trivial
xplanation—not invoking differential effector mech-
nisms—would be an enhanced in vivo expansion or
ersistence of the T2 subset. To address this question,
1 CFDA-labeled T1 or T2 cells and marrow were
njected into sublethally irradiated B6 or syngeneic F1
osts. T1 or T2 cells were nearly undetectable 4 hours
fter BMT but were easily quantiﬁed by 40 hours after
MT (Table 2). T1 cells were present in parental B6
osts in signiﬁcantly higher numbers than in T2 cells
3.1
 1.1 versus 0.9
 0.3 106 cells per spleen; P
019); similarly, upon transfer into syngeneic F1 hosts,
1 cells were also increased relative to T2 cells (4.2 

.1 versus 1.9 
 0.9  106 cells per spleen; P  .048).
1 cells were present in similar numbers after injec-
ion into parental or syngeneic hosts (3.1 
 1.1 versus
.2 
 2.1  106 cells per spleen; P  .219); however,
n marked contrast, T2 cells were signiﬁcantly re-
uced in parental hosts relative to syngeneic hosts
0.9
 0.3 versus 1.9
 0.9 106 cells per spleen; P
042). This reduction in splenic T2 cell number after
MT was not likely due to differential homing of the
1 versus T2 cells, because the absolute numbers of
hese populations in lymph nodes, bone marrow, and
hymus were similar (data not shown).
1-into-P Lethal Irradiation: Host T-Cell Addback
odel—T2 Abrogation of Rejection
Recently, a new graft-rejection model was intro-
uced [18] that has several advantages relative to the
ublethal irradiation model. In this model, lethal host
rradiation is administered, with subsequent host T-
ell addback provided as a source of immune-compe-
ent cells capable of mediating an HVG rejection
esponse. This model rules out stem cell competition
s a mechanism for engraftment failure and addition-
lly allows one to quantify the number of host T cells
able 2. Donor T2 Cell Number Is Reduced In Vivo during Abrogatio
ohort No.* Host XRT BMT
1 B6 700 F1
2 B6 700 F1
3 F1 700 F1
4 F1 700 F1
Parental B6 or syngeneic F1 mice were irradiated (XRT; 700 cG
CFDA-labeled F1 T cells (1  107) of the T1 phenotype (coho
Results were pooled from 2 experiments (n  6 total per cohort).
cells was calculated by ﬂow cytometry and absolute cell counts.hat form the immune engraftment barrier. Using a T
B&MTodiﬁed version of this model, we found that T2 cells
ffectively abrogated rejection in an F1-into-P strain
ombination in 55% (22/40) of cases (increased sur-
ival relative to rejection control survival of 11% [1 of
]; P  .007). Evaluation of T2 treatment subgroups
evealed several ﬁndings. First, low-dose T2 cell in-
usion (1  107 cells) abrogated rejection when ad-
inistered into hosts reconstituted with low or high
-cell numbers (10000 or 100000 T cells) and was not
ssociated with ongoing weight loss or other signs of
oxicity (not shown). However, high-dose T2 infusion
2.5 107 cells) was associated with lethality in 8 of 10
ases of infusion into hosts reconstituted with a low
ose of T cells; although this experiment was per-
ormed in an F1-into-P model, lethality in such recip-
ents appeared to be due to a GVHD-like syndrome
signiﬁcant weight loss and hunched posturing). Most
trikingly, the same high-dose T2 cell infusion, when
dministered to hosts reconstituted with higher T-cell
umbers (100000 T cells), resulted in less weight loss
not shown) and resulted in survival in 9 of 14 cases
64%) (Table 3).
1-into-P2 Lethal Irradiation: Host T-Cell
ddback Model—T2 Abrogation of Rejection
ith Reduced GVHD
We further evaluated whether co-stimulated T2
ells might prevent rejection in a lethal irradiation
ost T-cell addback model involving fully MHC-mis-
atched bidirectional alloreactivity (BALB/c [H-2d]
nto B6 [H-2b]). In this model, the administration of
nmanipulated donor T cells at doses of 1  106 or
 107 cells to hosts reconstituted with a low number
f T cells (10000 cells) resulted in clinical GVHD
progressive weight loss and hunched posturing) and
early uniform lethality within 1 month after BMT
95% of cases; 18/19 recipients; Table 4). In marked
ontrast, the administration of 1  107 co-stimulated
2 cells to hosts reconstituted with 10000 T cells was
ssociated with lethality in only 30% (3/10) of recip-
ents. Similar to the results in the F1-into-P lethal
rradiation model, administration of high-dose donor
7
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6n lethality in 100% of cases when hosts were recon-
tituted with only 10000 T cells. Most remarkably,
his high-dose T2 cell infusion was relatively well
olerated when hosts were reconstituted with 100000
cells (survival in 60% [6/10] of such recipients). In
his fully MHC-disparate model, survival in all T2
ecipients (irrespective of T2 cell dose or host T-cell
econstitution dose) was 42% (16/38), which was sig-
iﬁcantly improved relative to the 5% (1/19) survival
bserved in recipients of unmanipulated donor T cells
P  .0004).
ISCUSSION
In this study, we have demonstrated that CD3/
D28 co-stimulation of donor T cells under T1- or
2-promoting culture conditions rapidly generates
onor T cells highly polarized in cytokine secretion
able 3. F1-into-P Lethal Irradiation: Host T-Cell Addback Model—T
Cohort No.*
Host Factors
Host XRT T-Cell Addback
1 B6 1050 —
2 B6 1050 —
3 B6 1050 10 K
4 B6 1050 100 K
5 B6 1050 10 K
6 B6 1050 10 K
7 B6 1050 100 K
8 B6 1050 100 K
9 (3  4) (All T-cell addback reject
0 (5  6  7  8) (All T2 cell ther
Host B6 mice were lethally irradiated (1050 cGy; day 2 of BMT)
1 of BMT). BMT consisted of TCD F1 marrow cells with or
Mice were evaluated through day 30 after BMT for survival.
able 4. P1-into-P2 Host T-Cell Addback Model: T2 Abrogation of Re
Cohort No.*
Host Factors
Host XRT T Cells
1 B6 1050 —
2 B6 1050 —
3 B6 1050 10 K
4 B6 1050 100 K
5 B6 1050 10 K
6 B6 1050 10 K
7 B6 1050 10 K
8 B6 1050 10 K
9 B6 1050 100 K
0 B6 1050 100 K
1 (3  4) (All T-cell addback reject
2 (5  6) (All unmanipulated T-ce
3 (7  8  9  10) (All T2 cell thera
Host B6 mice were lethally irradiated (XRT; 1050 cGy; day 2 o
cells (day 1 of BMT). On the day of BMT, mice received TC
of 1  107 cells or 2.5  107 cells) or unmanipulated T cells (TMice were evaluated through day 30 after BMT for survival.
10attern. Similar to our prior results using third-party
lloreactive Tc2 cells [9], we found that co-stimulated
h2/Tc2 cells were more effective than control Th1/
c1 cells for the prevention of marrow rejection in an
1-into-parent sublethal irradiation model. We have
lso extended our prior results through identiﬁcation
f co-stimulated Th2/Tc2 cell efﬁcacy for rejection
brogation in lethal irradiation models involving F1-
nto-parent or P1-into-P2 transplantation that use host
-cell addback. Furthermore, our results identify that
he balance of host T-cell number and donor Th2/
c2 cell number is a crucial consideration for attempts
o prevent rejection with reduced GVHD.
The method we have developed to generate co-
timulated Th2/Tc2 cells uses CD28 signaling, which
as previously been shown to promote T-cell prolif-
ration and differentiation into either type 1 or type 2
ytokine–secreting subsets, depending on the cytokine
gation of Rejection
Donor Inocula Survival†
MT T2 Cells Incidence Statistics
— — 0% (0/5)
 — 80% (4/5)
 — 25% (1/4)
 — 0% (0/5)
 1  107 80% (8/10)
 2.5  107 20% (2/10)
 1  107 50% (3/6)
 2.5  107 64% (9/14)
trols) 11% (1/9)
55% (22/40) 10 vs 9 (P  .007)
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trols) 10% (1/10)
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42% (16/38) 13 vs 11 (P  .02)
13 vs 12 (P  .0004)
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Co-Stimulated Th2/Tc2 Cells Abrogate Marrow Rejection
Bicroenvironment [19]. Consistent with this litera-
ure, we found that CD3/CD28 co-stimulation of do-
or T cells in T1- or T2-promoting conditions re-
ulted in logarithmic expansion of T cells secreting
lassic type I and type II cytokine patterns as early as
ay 4 of culture. In addition, co-stimulation produced
1 and T2 effectors that were highly activated as
easured by MCV and cell-surface activation markers
nd possessed potent cytolytic function. The rapid and
igniﬁcant increase in T-cell effector function gener-
ted in this new system likely relates in part to the
rovision of signal 1 (TCR engagement) and signal 2
co-stimulation) through antibody-coated magnetic
eads, which obviates the potential negative regula-
ory signaling of the cytotoxic T lymphocyte antigen
CTLA-4) pathway [20] that occurs in systems using
PC as stimulators. Our development of murine mod-
ls that use Th2/Tc2 cells generated through an APC-
ree method has potential clinical translational impor-
ance, because co-stimulated T cells generated
ithout polarizing cytokines have been evaluated in
linical trials evaluating autologous T-cell therapy of
uman immunodeﬁciency virus disease [21] and com-
ined autologous hematopoietic stem cell and T-cell
herapy of leukemia [22] and lymphoma [23].
In this study, we found that co-stimulated T2 cells
ere most effective for rejection abrogation in the
1-into-P setting when administered at the time of
arrow infusion. Because in vitro studies demon-
trated that veto cells clonally delete pCTL within 24
o 72 hours of alloantigen exposure [6,17], we initially
ypothesized that donor T2 cells might more efﬁ-
iently abrogate rejection if administered in a delayed
anner after BMT. Contrary to our hypothesis, we
ound that even a 24- to 48-hour delay in T2 cell
dministration signiﬁcantly reduced their efﬁcacy.
his striking result suggests that host pCTL activa-
ion toward donor alloantigens may occur more rap-
dly in vivo than in vitro. Alternatively, donor T2 cells
ay promote alloengraftment in vivo through a non-
ytotoxic mechanism, such as type II cytokine secre-
ion; further studies using cytokine- or cytotoxic-de-
cient Th2/Tc2 populations will be required to better
nderstand the molecular mechanisms that contribute
o Th2/Tc2 cell-rejection abrogation. Nonetheless,
hese data indicate that clinical trials evaluating T2
ells to enhance alloengraftment may best use con-
omitant T2 cell and stem cell infusion.
Recently, a new graft-rejection model was intro-
uced that uses lethal host irradiation and subsequent
ost T-cell addback [18]. This model has 2 primary
dvantages relative to sublethal host irradiation mod-
ls. First, because lethal irradiation is administered,
ailure of engraftment and subsequent lethality can be
ore directly attributable to immune-mediated rejec-
ion, without consideration for stem cell competition
s a mechanism for lack of alloengraftment. Second, t
B&MTecause a deﬁned number of host T cells are added
ack after irradiation, the precise stoichiometry be-
ween donor and host T-cell numbers can be deﬁned,
hereby enhancing the study of this important im-
une balance. In our experiments using such an F1-
nto-P model that used lethal irradiation and host
-cell addback, we indeed found that co-stimulated
h2/Tc2 cells effectively prevented marrow rejection
n most T2 cell recipients (55%; 22/40 cases). This
esult is somewhat distinct from the recent report by
achar-Lustig et al. [18] that used third-party allo-
eactive veto cells, because a high frequency of en-
raftment was observed in that study only when veto
ell infusion was combined with post-BMT rapamycin
dministration. The capacity of co-stimulated Th2/
c2 cells to act alone in the prevention of rejection
ay indicate that this population is a particularly po-
ent facilitator of engraftment. However, it should be
ointed out that our experimental design did not fully
eplicate the prior study of Bachar-Lustig et al., be-
ause different irradiation doses, strain combinations,
ethods of host T-cell preparation, and donor mar-
ow sources were used.
In the F1-into-P lethal irradiation and host T-cell
ddback model, we unexpectedly observed lethality
ue to a GVHD-like syndrome in recipients of high-
ose Th2/Tc2 cells (2.5  107 cells per recipient) that
as critically dependent on the quantity of host T cells
resent after irradiation. This result was not antici-
ated, because we have previously found that co-stim-
lated Th2/Tc2 cells, when administered at a dose of
 107 cells per recipient in a P-into-F1 GVHD
odel involving lethal host irradiation, were not as-
ociated with signiﬁcant histologically deﬁned GVHD
r lethality. Our observation that this lethality oc-
urred in an F1-into-P model was particularly unex-
ected because the Th2/Tc2 cells were syngeneic rel-
tive to host MHC. It is possible that the Th2/Tc2
ells expanded after BMT in a homeostatic manner as
result of extensive host T-cell depletion (lethal irra-
iation with only 10000 host T-cell addback); along
he same lines, it is possible that lack of Th2/Tc2-
ediated GVHD in the prior P-into-F1 model may
ave resulted in part from T2 cell alloantigen-induced
ell death, a process that would not be operational in
he F1-into-P model.
Strikingly, the nearly uniform lethality observed in
igh-dose Th2/Tc2 recipients was not observed when
ost mice were reconstituted with a higher dose of T
ells. These ﬁndings indicate that donor Th2/Tc2
ells are susceptible to host resistance mechanisms
hat regulate unmanipulated donor T-cell populations
24], and they illustrate that the numerical balance
etween donor Th2/Tc2 cells and host immune-com-
etent T cells can dramatically inﬂuence the effect of
h2/Tc2 cell infusion. In this context, it is important
o note that our post-BMT cell-tracking studies de-
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6ermined that the Th2/Tc2 cell number was numeri-
ally reduced in vivo in the setting of an HVG reac-
ion (F1-into-P model) relative to syngeneic
ransplantation (F1-into-F1 model). On the basis of
hese data, it is interesting to speculate that CTL
eletion after BMT may be bidirectional in our
odel, with Th2/Tc2 cell elimination of host pCTL
or rejection abrogation and host pCTL elimination
f co-stimulated Th2/Tc2 cells for moderation of
h2/Tc2 cell expansion and toxicity.
We further found that a balance of donor Th2/
c2 cell number and postirradiation host T-cell num-
er could be deﬁned that prevented graft rejection
ith reduced GVHD in a P1-into-P2 model involving
ull MHC disparity in both HVG and graft-versus-
ost directions. When host mice were reconstituted
ith 10000 T cells after irradiation, administration of
nmanipulated donor T cells was nearly uniformly
ssociated with lethal GVHD, even at a relatively low
onor T-cell dose of 1  106 cells; in contrast, infu-
ion of 1  107 Th2/Tc2 cells effectively prevented
ejection without lethal GVHD in most cases. As
uch, co-stimulated Th2/Tc2 cells seem to have a
avorable therapeutic index relative to unmanipulated
cells for attempts to prevent graft rejection while
inimizing GVHD.
On a cautionary note, high-dose Th2/Tc2 cell
nfusion (2.5  107 cells) uniformly resulted in lethal
VHD in this setting of fully MHC-disparate trans-
lantation and nominal host resistance. However, re-
arkably, high-dose Th2/Tc2 infusion prevented re-
ection without lethal GVHD in most cases when a
igher level of host resistance was present. To address
his signiﬁcant issue of Th2/Tc2-mediated GVHD
hat can occur in both syngeneic and allogeneic set-
ings of nominal host resistance, future studies will
valuate Th2/Tc2 cells with reduced potential to me-
iate GVHD that are generated through in vitro rapa-
ycin exposure (Foley JE, Fowler DH, unpublished
ata). In summary, these ﬁndings demonstrate that
o-stimulated Th2/Tc2 cells, although associated with
educed GVHD relative to unmanipulated T cells,
an mediate signiﬁcant GVHD under conditions of
ominal host resistance. Clinical trials using co-stim-
lated Th2/Tc2 cells should be performed in a phase
manner, with an additional requirement for stan-
ardization of the quantitative level of host T-cell
esistance present at the time of Th2/Tc2 cell infu-
ion, similar to the approach we have recently piloted
n a clinical trial of reduced-intensity allogeneic he-
atopoietic stem cell transplantation [25].
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